Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;28(3):832-833.
doi: 10.1038/s41391-024-00892-2. Epub 2024 Sep 10.

Use of a Schelin catheter for transurethral intraprostatic anesthesia (TUIA) prior to iTIND procedure

Silvia Secco  1 , Alberto Olivero  2 , Mattia Longoni  3   4 , Paolo Dell'Oglio  2 , Stefano Tappero  2 , Edoardo Dibilio  2 , Tommaso Saccucci  2 , Giampaolo Siena  5 , Aldo Massimo Bocciardi  2 , Antonio Galfano  2 , Luca Cindolo  6
Affiliations

Use of a Schelin catheter for transurethral intraprostatic anesthesia (TUIA) prior to iTIND procedure

Silvia Secco et al. Prostate Cancer Prostatic Dis. 2025 Sep.

Abstract

Background/objectives: Endorsing the principles of minimal invasiveness in benign-prostatic hyperplasia (BPH) surgery, we conducted the first evaluation of transurethral intraprostatic anesthesia (TUIA) using Schelin catheter® (SC) prior to iTIND positioning.

Subjects/methods: Of 23 patients enrolled, 11 (48%) received TUIA via SC whereas the remaining underwent standard anesthesia protocol. Pain was assessed using visual analogue scale (VAS).

Results: No differences between cohorts were observed for pain during the device implantation and removal. Conversely, significantly lower median VAS scores were reported at 24- (1.0 vs. 3.0) and 48- (1.0 vs. 2.5) hour follow-up favoring TUIA.

Conclusions: SC TUIA offers effective pain control during iTIND procedures, supporting its use in outpatient settings.

PubMed Disclaimer

Conflict of interest statement

Competing interests: AO, ML, PD, ST, ED, TS, GS, AMB, AG, LC: no conflicts of interest to declare; SS: proctor iTIND (Medi-Tate LTd.®, Or Akiva, Israel).

References

    1. Nguyen DD, Li T, Ferreira R, Baker Berjaoui M, Nguyen ALV, Chughtai B, et al. Ablative minimally invasive surgical therapies for benign prostatic hyperplasia: A review of Aquablation, Rezum, and transperineal laser prostate ablation. Prostate Cancer Prostatic Dis. 2023;27:22–8. - PubMed
    1. Manfredi C, Arcaniolo D, Spatafora P, Crocerossa F, Fusco F, Verze P, et al. Emerging minimally invasive transurethral treatments for benign prostatic hyperplasia: a systematic review with meta-analysis of functional outcomes and description of complications. Minerva Urol Nephrol. 2022;74:389–99. - PubMed
    1. Amparore D, Fiori C, Valerio M, Schulman C, Giannakis I, De Cillis S, et al. 3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction. Prostate Cancer Prostatic Dis. 2020;24:349–57. - PubMed
    1. Amparore D, De Cillis S, Schulman C, Kadner G, Fiori C, Porpiglia F. Temporary implantable nitinol device for benign prostatic hyperplasia-related lower urinary tract symptoms: over 48-month results. Minerva Urol Nephrol. 2023;75:743–51. - PubMed
    1. Sibona M, Destefanis P, Vercelli E, Secco S, Gontero P, Cindolo L. Ejaculation physiology and dysfunction after BPH surgery: the role of the new MISTs. Prostate Cancer Prostatic Dis. 2023;26:475–82. - PubMed

LinkOut - more resources